Literature DB >> 9168186

Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.

M A Hudson1, L M McReynolds.   

Abstract

BACKGROUND AND
PURPOSE: The plasminogen activators urokinase and tissue plasminogen activator are enzymes that degrade proteins in tissue basement membranes and the extracellular matrix (a biomolecular complex surrounding individual cells in tissues that serves as a barrier between the cells and the vascular and lymph systems). The action of these enzymes allows tumor cells to escape their local environment and metastasize. Plasminogen activator activity can be influenced by the urokinase receptor, which is expressed on the surface of cells, and by the plasminogen activator inhibitors 1 and 2. Because bladder tumors differ in their propensity to invade local areas and distant sites, we studied the expression of both plasminogen activators, the two plasminogen activator inhibitors, and the urokinase receptor in four human bladder cancer cell lines (RT4, 253J, EJ, and T24) to see if there was an association between the expression of these proteins and tumor cell invasiveness in vitro.
METHODS: The expression of urokinase, tissue plasminogen activator, and the two inhibitors was measured by enzyme-linked immunosorbent assays of serum-free, cell-conditioned media (i.e., culture fluids). Cell surface expression of the urokinase receptor was assayed by flow cytometry, using an anti-receptor monoclonal antibody (Mab3936). The invasive capacity of untreated cells and of cells exposed to exogenous, high-molecular-weight urokinase was analyzed by use of Matrigel invasion chambers.
RESULTS: The four bladder cancer cell lines demonstrated differential expression of both plasminogen activators and both inhibitors; three of the cell lines (T24, EJ, and 253J) expressed the urokinase receptor. The four cell lines differed in their invasive potential in vitro. Neither expression of tissue plasminogen activator nor production of the inhibitors appeared to influence Matrigel invasion. EJ cells and 253J cells produced the highest levels of urokinase and demonstrated the greatest propensity for invasion; T24 cells, which produced only small amounts of urokinase, exhibited a low invasive potential. Pretreatment of T24 cells with exogenous high-molecular-weight urokinase markedly increased their invasiveness. Similar pretreatment of EJ and 253J cells increased their invasiveness as well. RT4 cells, which lacked urokinase receptor expression but produced moderate amounts of urokinase, were not invasive and did not become so after exposure to exogenous high-molecular-weight urokinase. Binding of Mab3936 to urokinase receptors inhibited Matrigel invasion.
CONCLUSIONS: To our knowledge, this is the first study demonstrating that bladder tumor cells express the urokinase receptor and that both receptor expression and urokinase expression are required for bladder tumor cell invasion in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168186     DOI: 10.1093/jnci/89.10.709

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

1.  Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.

Authors:  Attalla Farag El-Kott; Abdalla Mohamed Khalil; Ayman El-Meghawry El-Kenawy
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

2.  PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Authors:  Evan Gomes Giacoia; Makito Miyake; Adrienne Lawton; Steve Goodison; Charles J Rosser
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

3.  Multiplex protein signature for the detection of bladder cancer in voided urine samples.

Authors:  Charles J Rosser; Shanti Ross; Myron Chang; Yunfeng Dai; Lourdes Mengual; Ge Zhang; Jeongsoon Kim; Virginia Urquidi; Antonio Alcaraz; Steve Goodison
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

4.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  CCL18 in a multiplex urine-based assay for the detection of bladder cancer.

Authors:  Virginia Urquidi; Jeongsoon Kim; Myron Chang; Yunfeng Dai; Charles J Rosser; Steve Goodison
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

6.  Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

Authors:  C Fujiyama; A Jones; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

7.  Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice.

Authors:  Yang-Kyu Choi; Byung-Il Yoon; Yoon-Hoh Kook; Young-Suk Won; Jin-Hyun Kim; Chul-Ho Lee; Byung-Hwa Hyun; Goo-Taeg Oh; John Sipley; Dae-Yong Kim
Journal:  Jpn J Cancer Res       Date:  2002-02

8.  Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis.

Authors:  Lezhong Chen; Xinghuan Wang
Journal:  Oncol Lett       Date:  2018-10-05       Impact factor: 2.967

Review 9.  Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.

Authors:  Adel Gouri; Aoulia Dekaken; Khalid El Bairi; Arifa Aissaoui; Nihad Laabed; Mohamed Chefrour; Joseph Ciccolini; Gérard Milano; Sadek Benharkat
Journal:  Biomark Insights       Date:  2016-08-16

10.  Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Authors:  Niklas Klümper; Isabella Syring; Wenzel Vogel; Doris Schmidt; Stefan C Müller; Jörg Ellinger; David Adler; Johannes Brägelmann; Sven Perner
Journal:  Front Med (Lausanne)       Date:  2017-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.